This project was supported by an Australian Research Council Discovery Project grant (DP170101669) and conducted at the Australian Research Centre in Sex, Health and Society, La Trobe University and the National Drug Research Institute, Curtin University. The National Drug Research Institute is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvement Grants Fund. No pharmaceutical grants were received in the development of this study. JN is part-funded by the National Institute for Health Research Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King's College London. JN is also supported by the Pilgrim Trust. Joanne Neale has received honoraria and research grants from pharmaceutical companies: Camurus AB and Mundipharma International Ltd. PMD has been appointed as an unpaid member of the Australian Mundipharma Advisory Board for an intranasal naloxone formulation. PMD has received investigator-driven funding from Gilead Sciences Inc. for work related to hepatitis C treatment and an untied educational grant from Indivior for work related to the introduction of buprenorphine/naloxone into Australia.
ProceedingsDrug and Alcohol Review
Place of publicationHoboken, NJ
Name of conferenceAPSAD 2019 Conference
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.